Literature DB >> 17235314

Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction.

Waseem Qasim1, Taylor Mackey, Jo Sinclair, Ilenia Chatziandreou, Christine Kinnon, Adrian J Thrasher, H Bobby Gaspar.   

Abstract

Retroviral transfer of the Herpes Simplex thymidine kinase (HSVTK) suicide gene to donor T cells has been used as a safety strategy against graft-versus-host disease following allogeneic stem cell transplantation. The feasibility of this strategy in human studies has been demonstrated, but a number of limitations have become apparent. Preactivation of donor lymphocytes using mitogens or monoclonal antibodies is essential for retroviral transduction, but can compromise subsequent T-cell function in vivo. We report the application of lentiviral vectors for transduction of T cells in cytokine culture, without activation through the T-cell receptor. Using vectors encoding either enhanced green fluorescent protein or a truncated CD34/mutant HSVTK fusion selection/suicide construct, we investigated the properties of T cells after gene modification. We found that following cytokine stimulation, a fraction of T cells undergoes division, and transgene expression occurred predominantly in these cells. Antiviral and alloreactive responses were preserved in these populations, and in contrast to fully activated T cells, there was minimal perturbation of regulatory T-cell numbers. We conclude that the use of interleukin-7 for lentiviral transduction offers the greatest potential for gene transfer to T cells without loss of function, and is favored for the clinical production of suicide gene modified T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235314     DOI: 10.1038/sj.mt.6300042

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  18 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.

Authors:  Wei-Li Di; Fernado Larcher; Ekaterina Semenova; Gill E Talbot; John I Harper; Marcela Del Rio; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

3.  Sleeping beauty transposition from nonintegrating lentivirus.

Authors:  Conrad A Vink; H Bobby Gaspar; Richard Gabriel; Manfred Schmidt; R Scott McIvor; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

4.  Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38.

Authors:  Laurence Pearce; Liam Morgan; Thet Thet Lin; Saman Hewamana; R James Matthews; Silvia Deaglio; Clare Rowntree; Christopher Fegan; Christopher Pepper; Paul Brennan
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 5.  Advances in PET Detection of the Antitumor T Cell Response.

Authors:  M N McCracken; R Tavaré; O N Witte; A M Wu
Journal:  Adv Immunol       Date:  2016-04-05       Impact factor: 3.543

6.  Advances in Gene Delivery Systems.

Authors:  Kenya Kamimura; Takeshi Suda; Guisheng Zhang; Dexi Liu
Journal:  Pharmaceut Med       Date:  2011-10-01

Review 7.  Contributions of gene marking to cell and gene therapies.

Authors:  Cecilia N Barese; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2011-05-05       Impact factor: 5.695

Review 8.  Molecular immunology lessons from therapeutic T-cell receptor gene transfer.

Authors:  Sharyn Thomas; Hans J Stauss; Emma C Morris
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

9.  FOXRED1, encoding an FAD-dependent oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathy.

Authors:  Elisa Fassone; Andrew J Duncan; Jan-Willem Taanman; Alistair T Pagnamenta; Michael I Sadowski; Tatjana Holand; Waseem Qasim; Paul Rutland; Sarah E Calvo; Vamsi K Mootha; Maria Bitner-Glindzicz; Shamima Rahman
Journal:  Hum Mol Genet       Date:  2010-09-21       Impact factor: 6.150

Review 10.  Novel delivery methods to achieve immunomodulation.

Authors:  David J Gould; Yuti Chernajovsky
Journal:  Curr Opin Pharmacol       Date:  2007-07-03       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.